This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read IN8bio’s 8K filing here.
About IN8bio
IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.
Read More
- Five stocks we like better than IN8bio
- EV Stocks and How to Profit from Them
- 3 Construction Stocks Set to Surge on Tariff-Driven Demand
- How to Buy Cheap Stocks Step by Step
- Sirius XM: Why Berkshire Just Added Another 2.3 Million Shares
- What Are Dividend Contenders? Investing in Dividend Contenders
- McDonald’s Underwhelmed in Q4: Why Investors Shouldn’t Worry
